Non-Regulatory

May 27, 2019

Affibody Enters into Agreement with 3P Biopharmaceuticals for Production of ABY-035

Solna, Sweden, May 27, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced an agreement with 3P Biopharmaceuticals (“3P”) covering process development and GMP manufacturing of Affibody’s...

Read more

Non-Regulatory

March 20, 2019

Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule

Solna, Sweden & Boston, USA, March 20, 2019. Affibody AB and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune...

Read more

Non-Regulatory

April 22, 2016

Sobi™ Signs Licensing Agreement with Affibody for IL-1

Solna, Sweden, April 22, 2016 – Swedish Orphan Biovitrum AB (publ) (Sobi™) today announced that it has exercised its option to sign a licensing agreement with Swedish biotech company...

Read more

Non-Regulatory

April 13, 2016

Affibody AB enter into an Option Agreement regarding cancer-targeting molecules

Solna, Sweden, April 13, 2016 – Affibody AB (“Affibody”) today announced that the company has signed a Feasibility Study and Product Option Agreement with an unnamed partner.

Read more

Non-Regulatory

April 12, 2016

Affibody AB enter into an Option Agreement regarding IL-17-targeting molecules in Ophthalmology

Solna, Sweden, April 12, 2016 – Affibody AB (“Affibody”) today announced that the company has signed a Research License and Product Option Agreement with an unnamed partner.

Read more

Non-Regulatory

December 24, 2015

Affibody Licenses Albumod™ Half-life Extension Technology to MedImmune

Solna, Sweden, December 24, 2015. Affibody AB today announced that MedImmune has extended its Albumod™ platform licensing agreement

Read more

Non-Regulatory

December 1, 2015

Affibody receives clinical milestone from Daiichi Sankyo

Solna, Sweden, December 1, 2015. Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo...

Read more

Non-Regulatory

June 1, 2015

Affibody AB and Biotest AG enter into a Research License and Option Agreement regarding the Albumod™ platform

Dreieich, Germany and Solna, Sweden – Biotest AG and Affibody AB today announced that the companies have signed a Research License and Option Agreement.

Read more

Non-Regulatory

November 27, 2014

Nordic Nanovector and Affibody collaborate on advanced radio-immunotherapies program for Multiple Myeloma

Oslo, Norway and Solna, Sweden – Nordic Nanovector ASA and Affibody AB today announced that the companies have entered into a three-year collaborative research agreement to discover and develop...

Read more